Friday, 24 November 2023

**Plenary Room**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:00 - 13:00 | Cellular Therapy and Immunobiology Working Party Scientific Business Meeting  
Open for everybody |
| 13:00 - 14:00 | Lunch Break                                                            |
| 14:00 - 16:00 | Cellular Therapy and Immunobiology Working Party Scientific Business Meeting  
Open for everybody |
| 16:00 - 16:15 | Coffee Break                                                          |
| 16:15 - 17:15 | Joint Meeting                                                          |
| 17:15 - 18:00 | **Keynote Lecture**  
Placement of cellular therapies in treatment algorithm of PCDs  
Carlos Fernández de Larrea (ES) |

**Breakout Room**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:00 - 13:00 | Chronic Malignancies Working Party Scientific Business Meeting  
Open for everybody |
| 13:00 - 14:00 | Lunch Break                                                            |
| 14:00 - 16:00 | Chronic Malignancies Working Party Scientific Business Meeting  
Open for everybody |
| 16:00 - 16:15 | Coffee Break                                                          |
| 16:15 - 17:15 | Joint Meeting at Plenary Room                                         |
Saturday, 25 November 2023

Plenary Room

09:00 – 10:00  
**Session I: Basics of myeloma**  
*Chair: Meral Beksac (TR)*  
- 09:00-09:15  
  Diagnostic and treatment algorithm in MM  
  Patrick Hayden (IE)  
- 09:15-09:30  
  Diagnostic and treatment algorithm in amyloidosis  
  Monique Minnema (NL)  
- 09:30-09:45  
  Diagnostic and treatment algorithm in WM, MGCS, MGRS  
  Shirley D'Sa (UK)  
- 09:45-10:00  
  Q&A

10:00 – 11:00  
**Session II: Preclinical models in MM**  
*Chair: Florent Malard (FR)*  
- 10:00-10:15  
  Genomic evolution  
  Niels Weinhold (DE)  
- 10:15-10:30  
  Omics  
  Marc Raab (DE)  
- 10:30-10:45  
  Microbiome  
  Florent Malard (FR)  
- 10:45-11:00  
  Q&A

11:00 – 11:30  
Coffee Break

11:30 – 12:35  
**Session III: Immune microenvironment in disease**  
*Chairs: Joanna Drozd-Sokolowska (PL) – Kavita Raj (UK)*  
- 11:30-11:45  
  T-cells  
  Kim de Veirman (NL)  
- 11:45-12:00  
  NK cells  
  Michael O’Dwyer (IE)  
- 12:00-12:15  
  Mechanisms of EMD  
  Tomáš Jelinek (CZ)  
- 12:15-12:20  
  Case presentation: Refractory Multiple Myeloma with Challenging Extramedullary Disease  
  Esra Gülderen (TR)  
- 12:20-12:35  
  Q&A

12:35 – 13:35  
**Session IV: Novel cellular therapies**  
*Chair: Lydia Lee (UK)*  
- 12:35-12:45  
  Novel targets  
  Luis G. Rodríguez-Lobato (ES)  
- 12:45-12:55  
  NK cells, macrophages, fibroblasts  
  Niels Weinhold (DE)  
- 12:55-13:05  
  Harvesting the therapeutic potential of gdT cells for cancer immune therapies  
  Jürgen Kuball (NL)  
- 13:05-13:15  
  Immune signalling at the tumour: bone marrow niche in multiple myeloma: a view to a kill  
  Graeme Sullivan (IE)  
- 13:15-13:35  
  Q&A

13:35 - 14:35  
Lunch Break
14:35 – 15:20  
**Session V: Procedural aspects**  
*Chair: Stefan Schönland (DE)*

14:35-14:50  
Cell collection and manufacturing  
Christian Chabannon (FR)

14:50-15:05  
AI  
Alexander Oeser (DE)

15:05-15:20  
Q&A

15:20 – 16:05  
**Session VI: New and "old" kids on the block**  
*Chair: Gösta Gahrton (SE)*

15:20-15:35  
Finding the optimal drug combination for rrMM  
Fredrik Schjesvold (NO)

15:35-15:50  
Role of autograft  
Mauricette Michallet (FR)

15:50-16:05  
Q&A

16:05 – 16:35  
Coffee Break

16:35 – 17:30  
**Session VII: Current state of CAR-T in PCD**  
*Chair: Nico Gagelmann (DE)*

16:35-16:50  
Ide-cel and ciltia-cel: trial insights  
Yael Cohen (IL)

16:50-17:05  
Real-world and GOCART  
Nico Gagelmann (DE)

17:05-17:20  
Academic  
Lydia Lee (UK)

17:20-17:30  
Q&A

17:30 – 18:15  
**Keynote lecture**  
*Chair: Anna Sureda (ES)*

Lessons and new insights in allogeneic CAR-T and transplant  
Nicolaus Kröger (DE)
Saturday, 25 November 2023

**Breakout Room**

**Nurses’ track**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:10 – 09:15</td>
<td>Welcome</td>
</tr>
<tr>
<td>09:15 – 10:15</td>
<td><strong>Session I: Multiple myeloma, the basics, and new treatment options</strong></td>
</tr>
<tr>
<td>09:15–10:15</td>
<td>Multiple myeloma (the basics), new treatment options, and what’s important in the patients screening for CART cell therapy in the MM field (frail/unfit screening)</td>
</tr>
<tr>
<td></td>
<td>Laurent Garderet (FR)</td>
</tr>
<tr>
<td>10:15 – 11:00</td>
<td><strong>Session II (part I): Toxicity during CART cell therapy and bispecific</strong></td>
</tr>
<tr>
<td>10:15–11:00</td>
<td>CAR-T</td>
</tr>
<tr>
<td></td>
<td>To be announced</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:30 – 12:15</td>
<td><strong>Session II (part II): Toxicity during CART cell therapy and bispecific</strong></td>
</tr>
<tr>
<td>11:30–12:15</td>
<td>Bispecifics</td>
</tr>
<tr>
<td></td>
<td>Marianne Elshoud (NL)</td>
</tr>
<tr>
<td>12:15 – 13:15</td>
<td><strong>Session III: The role of the research nurse and nurse specialist in the patient Pathway (CART and bispecific)</strong></td>
</tr>
<tr>
<td>12:15–12:45</td>
<td>CAR-T</td>
</tr>
<tr>
<td></td>
<td>Sandy Kruyswijk (NL)</td>
</tr>
<tr>
<td>12:45–13:15</td>
<td>Bispecifics</td>
</tr>
<tr>
<td></td>
<td>Maaike de Ruijter (NL)</td>
</tr>
<tr>
<td>13:15 – 13:30</td>
<td>Closing Remarks</td>
</tr>
<tr>
<td>13:30 – 14:30</td>
<td>Lunch Break</td>
</tr>
</tbody>
</table>
Sunday, 26 November 2023

Plenary Room

09:00 - 10:00  Session VIII: Biology of response and relapse  
Chair: Annalisa Ruggeri (IT)
- 09:00-09:15 High-risk Myeloma transplant vs CART  
  Christoph Schaefers (DE)
- 09:15-09:30 Antigen loss and microenvironment  
  Sarah Gooding (UK)
- 09:30-09:45 Immune monitoring  
  Christof Scheid (DE)
- 09:45-10:00 Q&A

10:00 - 10:55  Industry Symposium on “Novel therapies in multiple myeloma”  
Kindly sponsored by Janssen  
Chair: Hermann Einsele (DE)
- 10:00-10:10 Novel immune and cellular therapies  
  Hermann Einsele (DE)
- 10:10-10:25 CAR T cells - patient selection and treatment of toxicities  
  Christof Scheid (DE)
- 10:25-10:40 Management of infections & mitigations strategies  
  Cyrus Khandanpour (DE)
- 10:40-10:55 Q&A

10:55 – 11:25  Coffee Break

11:25 – 12:25  Session IX: Monitoring and treating resistance  
Chair: Yael Cohen (IL)
- 11:25-11:40 Multi-targeting  
  Mohamad Mohty (FR)
- 11:40-11:55 Role of MRD  
  Noemi Puig (ES)
- 11:55-12:10 Bispecifics  
  Hermann Einsele (DE)
- 12:10-12:25 Q&A

12:25 – 13:25  Session X: Patient fitness and toxicities  
Chair: Donal McLornan (UK)
- 12:25-12:40 Is there “eligibility” for CAR-T?  
  Laurent Garderet (FR)
- 12:40-12:55 Mechanisms and strategies for neurotoxicity  
  Ibrahim Yakoub-Agha (FR)
- 12:55-13:10 Hematotoxicity and others  
  Meral Beksac (TR)
- 13:10-13:25 Q&A

13:25 – 13:40  Closing Remarks  
Donal McLornan (UK)
Annalisa Ruggeri (IT)